Clinical data | |
---|---|
Other names | PF-05314882; N-(3H-Imidazo(4,5-b)pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide |
Routes of administration | By mouth |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C27H34FN5O2 |
Molar mass | 479.600 g·mol−1 |
3D model ( JSmol) | |
| |
|
MK-0773, also known as PF-05314882, is a steroidal, orally active selective androgen receptor modulator (SARM) that was under development by Merck and GTx for the treatment of sarcopenia (loss of muscle mass) in women and men. [1] [2] [3] Clinical trials for sarcopenia began in late 2007 but the collaboration between Merck and GTx ended in early 2010 and GTx terminated development of MK-0773 shortly thereafter. [2] MK-0773 was developed as a more advanced version of the related compound TFM-4AS-1. [4]
MK-0773 is a 4-azasteroid [5] and a potent and selective agonist of the androgen receptor (AR). [1] It binds to the AR with an EC50 of 6.6 nM and is a partial agonist in transactivation modulation of the AR with an IP of 25 nM and Emax of 78% and has a TRAF2 Emax of 29% and an N/C interaction (virilization-related) counterscreen assay Emax of 2%. [1] That is, it produces promoter activation but induces the N/C interaction almost negligibly. [1] MK-0773 is reportedly four times as potent as testosterone as an agonist of the AR. [2] The drug is selective and does not bind to other steroid hormone receptors such as the progesterone receptor or glucocorticoid receptor and shows no significant inhibition of 5α-reductase (IC50 > 10 μM). [1] In addition, it is non- aromatizable and hence has no potential for estrogenic effects or side effects, like gynecomastia. [6] MK-0773 had similar effects on lipid metabolism relative to DHT, including a decrease in total cholesterol and high-density lipoprotein (HDL) of a similar magnitude. [1]
MK-0773 shows tissue-selective androgenic effects in vivo in animals. [1] It increases lean body mass with maximal anabolic effects that are approximately 80% of those of dihydrotestosterone (DHT). [1] However, it had less than 5% of the effect of DHT on uterine weight, about 30 to 50% of the increase of sebaceous gland area induced by DHT, and increased the weight of the seminal vesicles by 12% of that of DHT at the highest dosage assessed. [4] [1] It had similarly reduced effects on the prostate gland. [1] No significant increase in gene expression of six candidate genes related to virilization was observed. [7] As such, MK-0773 shows a profile of an anabolic SARM with limited effects on sebaceous glands and reproductive tissues in animals and a reduced propensity for virilization. [1]
In human clinical studies, MK-0773 produced anabolism in women and men while producing no or very low effects on sebaceous glands, the endometrium, or the prostate gland after 12 weeks of treatment. [1] [7] [8] [9] A decrease in total cholesterol and HDL was also observed in the clinical studies. [1] MK-0773 produced a significant increase in lean body mass in elderly (≥65 years of age) women with sarcopenia and moderate physical dysfunction. [10] [11] [12] It also increased muscle strength relative to placebo but this failed to reach statistical significance. [10] [12] MK-0773 has been associated with elevated liver enzymes in clinical studies. [10]